---
marp: true
theme: uncover
paginate: true
backgroundColor: #ffffff
style: |
  section { font-family: 'Helvetica', sans-serif; text-align: left; }
  header { color: #2c3e50; font-weight: bold; }
  footer { font-size: 15px; color: #7f8c8d; }
  .columns { display: grid; grid-template-columns: repeat(2, minmax(0, 1fr)); gap: 1rem; }
  .highlight { color: #d35400; font-weight: bold; }

title: Medicinal Chemistry of Benzodiazepines
footer: "PHA 548 | Hampton University | PY1 PharmD"
---

# üß¨ Medicinal Chemistry: Benzodiazepine Sedative-Hypnotics
**Course:** PHA 548 Pharmacology & Medicinal Chemistry  
**Instructor:** Sidney Bolden, Jr., Ph.D.

---

## üéØ Learning Objectives

1. **MOA:** Describe BZD interaction at the $GABA_A$ Œ±-Œ≥ interface.
2. **SAR:** Identify structural features driving potency and selectivity.
3. **PK/PD:** Predict metabolic pathways based on chemical substituents.
4. **Innovation:** Evaluate "Soft Drug" design (Remimazolam).

---

## $GABA_A$ Receptor: The Biological Target



<div class="columns">
<div>

**Key Concepts:**
* **Type:** Pentameric $Cl^-$ channel.
* **Binding Site:** $\alpha-\gamma$ interface.
* **Mechanism:** Increases **frequency** of opening.
* **Safety:** Requires GABA (Safety vs. Barbiturates).

</div>
<div>

![GABAA binding site](figures/BZ_Allosteric_Binding.jpg)

</div>
</div>

---

## üõ†Ô∏è The BZD Pharmacophore
**5-phenyl-1,4-benzodiazepine-2-one**



<div class="columns">
<div>

**Essential Anchors:**
1. **Ring A:** Aromatic; C7 electronegativity.
2. **Ring B:** C2-Carbonyl (H-bond).
3. **Ring C:** Phenyl ring ($\pi$-stacking).

</div>
<div>

![Backbone](figures/BZ_backbone.jpg)

</div>
</div>

---

## SAR ‚Äî The Molecular "Cheat Sheet"

| Site | Required Feature | Effect |
| :--- | :--- | :--- |
| **C7 (Ring A)** | Electronegative ($Cl/NO_2$) | **‚Üë affinity** |
| **C1 (Ring B)** | Small Alkyl | Optimal |
| **C3 (Ring B)** | **-OH Group** | **‚Üë Clearance** (Phase II) |
| **C2' (Ring C)** | Electronegative ($F/Cl$) | ‚Üë Potency |
| **C4' (Ring C)** | Bulk | **Abolishes activity** |

---

## üß™ Metabolism: The Oxidative Liability
### Long-Acting Agents (e.g., Flurazepam)



* **Pathway:** CYP3A4 N-dealkylation.
* **Issue:** Active metabolites accumulate.
* **Clinical:** Daytime sedation and cognitive decline in elderly patients.

![Flurazepam metabolism](figures/flurazepam_metabolism.jpg)

---

## ‚ö° Metabolism: The 3-OH Advantage
### (e.g., Temazepam, Oxazepam, Lorazepam)



* **Feature:** Presence of **C3-OH**.
* **Pathway:** Direct Phase II Glucuronidation.
* **Result:** No active metabolites; safer for liver impairment.

![Temazepam metabolism](figures/Temazepam_metabolism.jpg)

---

## üöÄ Modern Innovation: Remimazolam (Byfavo)
**"Soft Drug" Evolution**



* **Design:** Carboxylic ester side chain.
* **Metabolism:** Tissue esterases (Independent of CYPs).
* **Benefit:** Predictable, ultra-short sedation for procedures.

![Remimazolam](figures/Remimazolam-metabolism.jpg)

---

## üìä Comparative PK Summary

| Drug | Metabolism Route | PK Outcome |
| :--- | :--- | :--- |
| **Flurazepam** | CYP3A4 | Long-acting metabolites |
| **Estazolam** | Fused Triazolo ring | Intermediate duration |
| **Temazepam** | Direct Conjugation | Rapid clearance |
| **Remimazolam**| Ester Hydrolysis | Ultra-short duration |

---

## üß† PY1 Critical Thinking Exercise

**Predict the outcome of these structural changes:**

1. **Remove C7-Cl:** Activity lost.
2. **Para-substitution on Ring C:** Activity lost.
3. **Adding a Triazolo ring:** Increases potency; blocks certain oxidation sites.

---

# Questions?
**Next:** Non-BZD Hypnotics (The Z-Drugs).
